More articles from Interpreting Key Trials

  • TheDASHdiet for high blood pressure: From clinical trial to dinner table
    Njeri Karanja, PhD, T.P. Erlinger, MD, MPH, Lin Pao-Hwa, PhD, Edgar R. Miller, MD, PhD and George A. Bray, MD
    Cleveland Clinic Journal of Medicine September 2004, 71 (9) 745-753;

    Eating right lowers blood pressure by about as much as any single antihypertensive drug—but will patients do it?

  • Lessons from the PROVE-IT Trial
    Kiran K. Khush, MD and David Waters, MD
    Cleveland Clinic Journal of Medicine August 2004, 71 (8) 609-616;

    Patients with acute coronary syndromes should receive aggressive lipid-lowering therapy with a statin in high doses. Goal low-density lipoprotein levels may need to be lower.

  • Angiotensin-receptor blockers in heart failure
    Shyam Bhakta, MD and Mark E. Dunlap, MD
    Cleveland Clinic Journal of Medicine August 2004, 71 (8) 665-673;

    The ARB candesartan was not only a good alternative to an ACE inhibitor, it was beneficial when added to a regimen that already included an ACE inhibitor and a beta-blocker.

  • ALLHAT says diuretics are better; ANBP2 says ACEs are better—Can we resolve the differences?
    Donald G. Vidt, MD
    Cleveland Clinic Journal of Medicine February 2004, 71 (2) 145-150;

    Two major clinical trials apparently differed about which class of drugs is best for high blood pressure. Or did they?

  • Interpreting the COMET trial
    W.H. Wilson Tang, MD, Michael Militello, PharmD and Gary S. Francis, MD
    Cleveland Clinic Journal of Medicine December 2003, 70 (12) 1081-1087;

    Although survival was better with carvedilol than with immediate-release metoprolol tartrate, we must increase the use of any approved beta-blocker in heart failure.

  • The Heart Protection Study: High-risk patients benefit from statins, regardless of LDL-C level
    Hitinder S. Gurm, MBBS and Byron Hoogwerf, MD
    Cleveland Clinic Journal of Medicine November 2003, 70 (11) 991-997;

    Nearly all patients at high risk of a coronary event should be taking a statin drug, regardless of their low-density lipoprotein level. We explain the rationale, design, findings, and implications of this important study.

  • In refractory temporal lobe epilepsy, consider surgery sooner
    Redeepak Lachhwani, MB, BS, MD and Hans Lüders, MD, PhD
    Cleveland Clinic Journal of Medicine July 2003, 70 (7) 649-653;

    Epilepsy surgery is perhaps the most underused therapy in all of medicine today.

  • Atrial fibrillation: Rate control is as good as rhythm control for some, but not all
    Mina K. Chung, MD
    Cleveland Clinic Journal of Medicine June 2003, 70 (6) 567-573;

    Many clinicians are questioning the need to restore or maintain sinus rhythm in atrial fibrillation. What did four recent trials show ?

  • The Lescol Intervention Prevention Study (Lips)
    Adrian W. Messerli, MD, Herbert D. Aronow, MD, MPH and Dennis L. Sprecher, MD
    Cleveland Clinic Journal of Medicine June 2003, 70 (6) 561-566;

    The trial showed a significant reduction in cardiac events in patients who received a statin drug immediately after a successful percutaneous coronary intervention. Currently, this is seldom done.

  • A Perspective on the study of Moseley et al
    Joseph Bernstein, MD and Tony Quach, BA
    Cleveland Clinic Journal of Medicine May 2003, 70 (5) 401-410;

    A provocative study suggests that arthroscopy for osteoarthritis of the knee provides subjective pain relief via a placebo effect.

Pages